Folic acid-tripeptide-conjugated synthetic biodegradable nanoparticle-loaded with Ormeloxifene potentially inhibited breast cancer xenograft tumor

Ramkrishna Sen,Julekha Kazi,Alankar Mukherjee,Biswajit Mukherjee
DOI: https://doi.org/10.1016/j.jddst.2024.105750
IF: 5
2024-05-11
Journal of Drug Delivery Science and Technology
Abstract:Highlights • Folic acid peptide surface functionalized nanocarrier (FA-Pep-OLF-NP) exhibited distinct superior therapeutic efficacy and selective apoptosis in breast cancer cells (MDA-MB-231 and MCF-7). • FA-Pep-OLF-NP were found to be stable and non-toxic to normal cells, thus promising to be a safe and effective therapeutic intervention in the treatment of breast cancer. • In-vivo biodistribution with 99m-Tc was performed to evaluate the MDA-MB-231 bearing tumor uptake. Objectives Ormeloxifene (OLF) is an estrogen receptor modulator used in breast cancer treatment with highly favorable pharmacodynamics and pharmacokinetic properties. Folic acid (FA) receptor overexpresses in breast cancer cells. Hence, the study was intended to evaluate the therapeutic potential of OLF-encapsulated FA-peptide-conjugated nanoparticles (FA-Pep-OLF-NP) for breast cancer treatment. Methods We prepared folic acid tripeptide conjugated OLF-encapsulated PLGA nanoparticles. The surface conjugation of folic acid-tripeptide was assessed by FTIR and XPS analysis. Selectivity, cytotoxicity, apoptosis, mitochondrial depolarization, reactive oxygen species, and cell cycle analysis of the experimental nanoparticles were tested on human breast cancer cells, MDA-MB-231 and MCF-7. The therapeutic efficacy of FA-Pep-OLF-NP and unconjugated nanoparticle OLF-NP was compared in the MDA-MB-231-xenograft tumor animal model. Results OLF-NP and FA-Pep-OLF-NP exhibited 4.8 % and 4.5 % w/w of drug loading , respectively. The particles were spherical with a smooth surface and uniform size distribution. FA-Pep-OLF-NP revealed higher cytotoxicity, mitochondrial depolarization, and apoptosis potential in MDA-MB-231 cells compared to MCF-7 cells. Tumor uptake and tumor volume reduction by FA-Pep-OLF-NP and OLF-NP were established in MDA-MB-231 tumor-bearing nude mice. Conclusion FA-Pep-OLF-NP showed preferential delivery of OLF to the breast cancer cells and in breast tumors compared to OLF-NP and showed more drug accumulation in breast cancer xenograft models. FA-Pep-OLF-NP delayed the progress of folate receptor overexpressed breast cancer. Graphical abstract Ormeloxifene (OLF) nanoparticles conjugated with folic acid-tripeptide exhibited significant in apoptosis and reduced MDA-MB-231 xenograft tumor. Abbreviation: (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, Hexafluorophosphate Benzotriazole Tetramethyl Uronium) (HBTU), Hydroxybenzotriazole (HOBt), N,N-Diisopropylethylamine (DIPEA). Download : Download high-res image (316KB) Download : Download full-size image
pharmacology & pharmacy
What problem does this paper attempt to address?